Evidence map›Paper›PMID 40850308›Full record

ArticleNeoplasia (New York, N.Y.)2025

A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAF

Jiang Zhou, Xinxin Chai, Yi Zhu, Zhi Huang, Tingting Lin, Zhen Hu, Guangdi Chen, Chi Luo, Rutao Cui, Jinghao Sheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiang ZhouInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University, Hangzhou 311121, China; Skin Disease Research Institute, The 2nd Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Cancer Center, Zhejiang University, Hangzhou 310058, China.
Xinxin ChaiInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Yi ZhuInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University, Hangzhou 311121, China.
Zhi HuangInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Tingting LinInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Zhen HuInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Guangdi ChenInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Chi LuoLiangzhu Laboratory, Zhejiang University, Hangzhou 311121, China. Electronic address: chi.luo@alumni.tufts.edu.
Rutao CuiSkin Disease Research Institute, The 2nd Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China. Electronic address: rutaocui@zju.edu.cn.
Jinghao ShengInstitute of Environmental Medicine and Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University, Hangzhou 311121, China; Skin Disease Research Institute, The 2nd Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China; Cancer Center, Zhejiang University, Hangzhou 310058, China. Electronic address: jhsheng@zju.edu.cn.

Funding

Fundamental Research Funds for Zhejiang Provincial UniversitiesLeading Innovation and Entrepreneur Team of HangzhouNational Key Research and Development Program of China
6 · The paper itself

Abstract

The BRAF

Indexed as

Drug Resistance, NeoplasmHistonesMelanomaMutationProto-Oncogene Proteins B-rafAcetylationAnimalsBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingMethylationBRAF protein, humanBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsEnhancer of Zeste Homolog 2 ProteinHistonesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTranscription FactorsBRAF(V600E)H3K27KDM6AMelanomaMitochondrial MetabolismPGC1α

Identifiers

PMID40850308
PMCPMC12446969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.